ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - תמיסה להזרקה - treprostinil as sodium 5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - תמיסה להזרקה - treprostinil as sodium 2.5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.